Trial · NCT03037580
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in 6MWD From Baseline to Week 24 | Oral Treprostinil | 21.0 | Full Range -195 to 62 | meters | |
| Change in 6MWD From Baseline to Week 24 | Placebo | 23.3 | Full Range -140 to 104 | meters | |
| Change in NT-proBNP Levels From Baseline to Week 24 | Oral Treprostinil | 9.5 | Full Range -133 to 499 | pmol/L | |
| Change in NT-proBNP Levels From Baseline to Week 24 | Placebo | 11.5 | Full Range -231 to 172 | pmol/L | |
| Number of Subjects With First Clinical Worsening Event From Baseline to Week 24 | Oral Treprostinil | First Clinical Worsening Event | 6 | Participants | |
| Number of Subjects With First Clinical Worsening Event From Baseline to Week 24 | Placebo | First Clinical Worsening Event | 5 | Participants | |
| Number of Subjects With First Clinical Worsening Event From Baseline to Week 24 | Oral Treprostinil | No clinical worsening event | 35 | Participants | |
| Number of Subjects With First Clinical Worsening Event From Baseline to Week 24 | Placebo | No clinical worsening event | 38 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Oral Treprostinil | Baseline / WHO FC I | 1 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Placebo | Baseline / WHO FC I | 1 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Oral Treprostinil | Baseline / WHO FC II | 19 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Placebo | Baseline / WHO FC II | 17 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Oral Treprostinil | Baseline / WHO FC III | 21 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Placebo | Baseline / WHO FC III | 24 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Oral Treprostinil | Baseline / WHO FC IV | 0 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Placebo | Baseline / WHO FC IV | 1 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Oral Treprostinil | Baseline / Not analyzed | 0 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Placebo | Baseline / Not analyzed | 0 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Oral Treprostinil | Week 24 / WHO FC I | 4 | Participants | |
| Change in WHO FC From Baseline to Week 24 | Placebo | Week 24 / WHO FC I | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03037580/results